Colorectal cancer resource library

    Showing 1–20 of 21 results

    Filtered By:
    Blog

    FDA approves new treatment for metastatic CRC with BRAF mutation

    The U.S. Food and Drug Administration has approved encorafenib (marketed as BRAFTOVI) in combination with cetuximab (marketed as ERBITUX) as a second-line therapy for the treatment of adult patients with metastatic colorectal cancer with a BRAFV600E mutation.

    Blog

    Lynch syndrome: Common questions and answers

    Lynch syndrome runs in families from one generation to the next and leads to the most common inherited form of colorectal cancer, also called hereditary non-polyposis colorectal cancer (HNPCC).

    Janice Johnson: Get Informed & Advocate for Yourself
    Blog

    Janice Johnson: get informed and advocate for yourself

    When Janice Johnson started experiencing sudden GI symptoms at the age of 48, a cancer diagnosis was the last thing she expected. In fact, it was difficult for her to even get a colonoscopy in the first place, being that the recommended screening age was 50 at the time (2016).

    A photograph of Lexie in a chemotherapy chair.
    Blog

    Lexie Haglund: Beating stage IV CRC

    Discover how knowing her G12C biomarker guided Lexie’s stage IV colorectal cancer treatment — from a shock diagnosis to HIPEC surgery — and why screening, research, and self-advocacy matter.

    The main corridor at the 2025 ASCO Annual Meeting
    Blog

    2025 ASCO update: Six big studies

    The 2025 ASCO Annual Meeting featured several important studies that could change how colorectal cancer is treated, including a pivotal study for BRAF V600E patients.

    First FDA-Approved Treatment for HER2-Positive Colorectal Cancer
    Blog

    First FDA-approved treatment for HER2-positive colorectal cancer

    “Historically, patients with HER2-positive metastatic colorectal cancer who have progressed following frontline therapy have had poor outcomes,” said John Strickler, M.D. and lead investigator of the MOUNTAINEER trial. “The FDA approval of a chemotherapy-free combination regimen that specifically targets HER2 is great news for these patients.”

    support group three people

    Get connected with your allies

    There are many ways to find your community through the Alliance. Try one of our online communities.

    Learn More